ECSP066694A - TRANSDERMAL ADMINISTRATION HORMONES THAT DO NOT NEED PENETRATION POTENTIATORS - Google Patents

TRANSDERMAL ADMINISTRATION HORMONES THAT DO NOT NEED PENETRATION POTENTIATORS

Info

Publication number
ECSP066694A
ECSP066694A EC2006006694A ECSP066694A ECSP066694A EC SP066694 A ECSP066694 A EC SP066694A EC 2006006694 A EC2006006694 A EC 2006006694A EC SP066694 A ECSP066694 A EC SP066694A EC SP066694 A ECSP066694 A EC SP066694A
Authority
EC
Ecuador
Prior art keywords
hormones
patch
potentiators
transdermal administration
need
Prior art date
Application number
EC2006006694A
Other languages
Spanish (es)
Inventor
Michael Dittgen
Stefan Bracht
Petra Huber
Thomas Langguth
Dirk Schenk
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34702342&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066694(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of ECSP066694A publication Critical patent/ECSP066694A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7076—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere a un parche que comprende una capa de droga con un bajo contenido de hormonas, como por ejemplo gestodeno, y opcionalmente un estrógeno (por ejemplo etinilestradiol). Al aplicar el parche a una mujer, se consiguen niveles en plasma de al menos 1,0 ng/ml de gestodeno en condiciones de estado estacionario sin necesidad de incorporar potenciadores de penetración ni mejoradores de permeación en la capa que contiene droga. También son satisfactorios los niveles en plasma de las hormonas que se consiguen durante todo un período de al menos 1 semana, haciendo que el parche se pueda aplicar para utilizarlo en anticoncepción femenina con el concepto de aplicar el parche una vez a la semanaThe present invention relates to a patch comprising a drug layer with a low content of hormones, such as, for example, gestin, and optionally an estrogen (for example ethinyl estradiol). By applying the patch to a woman, plasma levels of at least 1.0 ng / ml of signodene are achieved under steady state conditions without the need to incorporate penetration enhancers or permeation enhancers in the drug-containing layer. Plasma levels of hormones that are achieved over a period of at least 1 week are also satisfactory, making the patch can be applied for use in female contraception with the concept of applying the patch once a week

EC2006006694A 2003-12-12 2006-07-11 TRANSDERMAL ADMINISTRATION HORMONES THAT DO NOT NEED PENETRATION POTENTIATORS ECSP066694A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52871803P 2003-12-12 2003-12-12
EP03078881 2003-12-12

Publications (1)

Publication Number Publication Date
ECSP066694A true ECSP066694A (en) 2006-10-31

Family

ID=34702342

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006694A ECSP066694A (en) 2003-12-12 2006-07-11 TRANSDERMAL ADMINISTRATION HORMONES THAT DO NOT NEED PENETRATION POTENTIATORS

Country Status (15)

Country Link
JP (1) JP4965263B2 (en)
KR (1) KR101168449B1 (en)
CN (1) CN1913878B (en)
AU (1) AU2004298930B2 (en)
BR (1) BRPI0417530B8 (en)
CA (1) CA2549916C (en)
CU (1) CU23868B1 (en)
EA (1) EA011160B1 (en)
EC (1) ECSP066694A (en)
IL (1) IL176112A (en)
MX (1) MXPA06006682A (en)
NO (1) NO341989B1 (en)
NZ (1) NZ548091A (en)
WO (1) WO2005058287A2 (en)
ZA (1) ZA200605713B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE333271T1 (en) 2003-02-21 2006-08-15 Schering Ag UV-STABLE TRANSDERMAL PLASTER
US8962013B2 (en) 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
DE102005050729A1 (en) * 2005-10-19 2007-04-26 Schering Ag Method of preventive on-demand hormonal contraception
FR2900048B1 (en) * 2006-04-21 2012-11-16 Oreal COMPOSITIONS COMPRISING A DIPHENYL-METHANE HYDROXYLATED DERIVATIVE
AU2015203180B2 (en) * 2010-09-06 2016-06-30 Bayer Intellectual Property Gmbh Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)
DE102010040299A1 (en) 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)
DK2613772T3 (en) 2010-09-06 2017-03-06 Bayer Ip Gmbh TRANSDERMAL LOW DOSAGE PATTERNS WITH HIGH PHARMACEUTICAL RELEASE
US20130195956A1 (en) * 2012-01-27 2013-08-01 Agile Therapeutics, Inc. Transdermal Hormone Delivery
EP3297634A1 (en) * 2015-05-18 2018-03-28 Agile Therapeutics, Inc. Contraceptive compositions and methods for improved efficacy and modulation of side effects

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE132751T1 (en) * 1988-10-27 1996-01-15 Schering Ag AGENTS FOR TRANSDERMAL APPLICATION CONTAINING STODENE
PT99338A (en) * 1990-10-29 1992-10-30 Alza Corp METHOD FOR THE PREPARATION OF COMPOSITIONS OF CONTRACEPTIONAL DRUGS ADMINISTERED TRANSDERMICALLY CONTAINING A MIXTURE OF ESTROGEN AND GESTODENE AND DEVICES FOR ITS TRANSDERMMIC ADMINISTRATION
US5512292A (en) * 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
DE4329242A1 (en) * 1993-08-26 1995-03-02 Schering Ag Agent for transdermal application containing gestodenester
DE4405898A1 (en) * 1994-02-18 1995-08-24 Schering Ag Transdermal therapeutic systems containing sex steroids
WO1996015776A1 (en) * 1994-11-18 1996-05-30 Hisamitsu Pharmaceutical Co., Inc. Percutaneously absorbable patch
JP3534775B2 (en) * 1995-06-07 2004-06-07 オーソ―マクニール ファーマシューティカル，インコーポレイテッド Transdermal patches and methods for administering 17-deacetylnorgestimate alone or in combination with estrogens
JP4346696B2 (en) * 1996-05-28 2009-10-21 久光製薬株式会社 Transdermal therapeutic device
JP4167750B2 (en) * 1997-04-16 2008-10-22 久光製薬株式会社 Transdermal absorption base and percutaneous absorption preparation containing the base
JP4399044B2 (en) * 1998-10-14 2010-01-13 久光製薬株式会社 Absorption enhancer and transdermal absorption preparation comprising the absorption enhancer
DE19906152B4 (en) * 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Active substance-containing laminates for transdermal systems
EP1197212A4 (en) * 1999-07-01 2004-06-02 Hisamitsu Pharmaceutical Co Adhesive preparation for percutaneous absorption
DE10053375C1 (en) * 2000-10-27 2002-01-24 Lohmann Therapie Syst Lts Transdermal therapeutic system with light-sensitive agent in polymer matrix and backing, useful for therapy with e.g. nicotine, nifedipine, lacidipine, gestagen, vitamin B 12 or antibiotic, contains colorless ultraviolet absorber
AU2002235155A1 (en) * 2000-12-05 2002-06-18 Noven Pharmaceuticals, Inc. Crystallization inhibition of drugs in transdermal drug delivery systems

Also Published As

Publication number Publication date
KR101168449B1 (en) 2012-07-25
AU2004298930B2 (en) 2009-11-26
EA200601089A1 (en) 2006-12-29
NO20062594L (en) 2006-07-10
AU2004298930A1 (en) 2005-06-30
CA2549916C (en) 2013-09-17
MXPA06006682A (en) 2006-08-11
JP4965263B2 (en) 2012-07-04
CA2549916A1 (en) 2005-06-30
IL176112A (en) 2011-02-28
CN1913878A (en) 2007-02-14
ZA200605713B (en) 2008-01-08
BRPI0417530B1 (en) 2018-01-23
NO341989B1 (en) 2018-03-12
CU23868B1 (en) 2013-03-27
WO2005058287A2 (en) 2005-06-30
IL176112A0 (en) 2006-10-05
CN1913878B (en) 2010-05-26
NZ548091A (en) 2009-12-24
EA011160B1 (en) 2009-02-27
WO2005058287A3 (en) 2006-03-02
BRPI0417530A (en) 2007-03-13
CU20100143A7 (en) 2011-10-31
JP2007513938A (en) 2007-05-31
KR20060128910A (en) 2006-12-14
BRPI0417530B8 (en) 2021-05-25

Similar Documents

Publication Publication Date Title
CU20100143A7 (en) TRANSDERMAL ADMINISTRATION HORMONES THAT DO NOT NEED PENETRATION POTENTIATORS
CY1115064T1 (en) HYDRAULIC INTERDERATIVE HYMN TRADE SYSTEM WITHOUT LEADING AID
DK0836506T4 (en) Transdermal patch for administration of 17-deacetyl norgestimate alone or in combination with an estrogen
AU4451101A (en) Method and compositions for preventing hormone induced adverse effects
BR0312007A (en) Transcutaneous administration rate control using amorphous pharmaceutical compositions
NO993520L (en) Dosage forms and methods for better erectile dysfunction
AR013520A1 (en) METHOD OF PREPARING A TRANSDERMAL ADMINISTRATION DEVICE, TRANSDERMAL ADMINISTRATION DEVICE AND USE OF A STEROID AS AN ADDITIVE IN A TRANSDERMAL ADMINISTRATION DEVICE
KR890011585A (en) Transdermal Contraceptives
CA3010829A1 (en) Gel compositions for transdermal delivery to maximize drug concentrations in the stratum corneum and serum and methods of use thereof
MXPA04005211A (en) Transdermal therapeutic systems containing steroid hormones and propylene glycol monocaprylate.
AR021459A1 (en) PATCH CONTAINING ESTRADIOL FOR THE PERCUTANEOUS APPLICATION OF HORMONES.
PE20040068A1 (en) ETONOGESTREL DECANOATE, UNDECANOATE AND DODECANOATE
ATE382356T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING ESTETROL DERIVATIVES AND USE IN CANCER TREATMENT
AR049197A1 (en) HORMONAL CONTRACEPTIVE CONTAINING A COMBINATION OF ETHYLINESTRADIOL AND CLORMADINONE ACETATE
UY28668A1 (en) TRANSDERMAL ADMINISTRATION HORMONES THAT DO NOT NEED PENETRATION POTENTIATORS
CU23649B7 (en) TRANSDERMAL ADMINISTRATION HORMONES THAT DO NOT NEED PENETRATION POTENTIATORS
CR8059A (en) PHARMACEUTICAL COMPOSITION IN THE FORM OF HYDROGEL FOR TRANSDERMAL ADMINISTRATION OF ACTIVE SUBSTANCES
PE20070119A1 (en) NEW REGIMES FOR CONTROLLED DELIVERY DEVICES FOR CONTRACEPTION DRUGS
KR960021015A (en) Transdermal Patches
ATE269063T1 (en) FORMULATIONS FOR TRANSDERMAL ADMINISTRATION OF FENOLDOPAM
TH115856A (en) The delivery of hormones through the skin without the need for infiltrating agents.